Back to Search
WILLIAM WEGENER, MD
MD
Nuclear Medicine Physician
NPI: 1992088975Individual
Specialties, Licenses & Credentials
Nuclear Medicine PhysicianPrimary
Nuclear Medicine
Code: 207U00000X
MD042734E(PA)25MA07350900(NJ)
Research & Publications (19)
Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration.
PMID 10855627·J Nucl Med·2000
3-trial
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
PMID 19451441·J Clin Oncol·2009
3-trial
Network "Rodent-borne pathogens" in Germany: longitudinal studies on the geographical distribution and prevalence of hantavirus infections.
PMID 19030894·Parasitol Res·2008
6-review
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
PMID 18853418·Cancer·2008
3-trial
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
PMID 18669463·J Clin Oncol·2008
3-trial
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
PMID 18268287·Haematologica·2008
3-trial
Nephropathia epidemica in metropolitan area, Germany.
PMID 17953116·Emerg Infect Dis·2007
7-preclinical
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
PMID 16864854·J Clin Oncol·2006
3-trial
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
PMID 16859536·Arthritis Res Ther·2006
3-trial
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
PMID 16630358·Arthritis Res Ther·2006
3-trial
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
PMID 16170184·J Clin Oncol·2005
3-trial
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
PMID 16033839·Clin Cancer Res·2005
3-trial
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
PMID 15955901·J Clin Oncol·2005
3-trial
Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.
PMID 15644390·Rheumatology (Oxford)·2005
5-case
Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent.
PMID 15359387·J Pediatr Surg·2004
3-trial
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
PMID 15328168·Clin Cancer Res·2004
3-trial
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
PMID 12837807·J Clin Oncol·2003
3-trial
Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma.
PMID 10897007·Cancer·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 22 STANFIELD AVE
BROOMALL, PA 19008 - Phone
- (610) 353-4738
Quick Facts
- NPI
- 1992088975
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 19
Are you this provider?
Claim Your Profile